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Summary
Most osteoporotic patients complain of back pain one
year after a fragility vertebral fracture and the frequency
of chronic back pain increases with increasing age. The
use of the lowest effective dose of an analgesic which is
able to control symptoms seems to be a possible solu-
tion in order to limit potential side effects in multi-treat-
ed elderly patients. Non-steroidal anti-inflammatory
drugs (NSAIDs) have a proven efficacy in the treatment
of back pain associated with fragility vertebral fractures
and diclofenac is available at low-dose subcutaneous in-
jective formulation. This is the rational of ImPAVeDic
study, acronym of Improvement of back Pain Associated
with fragility Vertebral fractures with low-dose Di-
clofenac, an observational study that will be performed
in a group of 50 elderly (≥ 65 years), male and female os-
teoporotic patients with symptomatic fragility vertebral
fractures. The objective of the study is to evaluate the
improvement of back pain in the study population treat-
ed with low-dose diclofenac and regularly monitored for
2-6 months. Visual Analogic Scale (VAS) and Numerical
Rating Scale (NRS) will be used for pain monitoring. The
reduction of the risk of occurrence of drug side effects
can favour the optimization of elderly patients’ care.
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Introduction
ImPAVeDic study, acronym of Improvement of back Pain As-
sociated with fragility Vertebral fractures with low-dose Di-
clofenac, is a longitudinal, prospective, observational No
Profit study which has been recently approved by local
Ethics Committee. 
Clinical basis and implications and specific features of Im-
PAVeDic study are described in the present mini-review.
Clinical basis and rational of ImPAVeDic study
Osteoporosis is a pathological condition characterized by in-
creased bone fragility due to reduced bone mass and/or poor
bone quality, thus leading to increased fracture risk (1, 2). 
Epidemiological data indicate that osteoporosis is more fre-
quent not only in females, but also in the elderly population.
In fact, 22 millions of women and 5.5 millions of men are cur-
rently known to be affected by osteoporosis within the Euro-
pean Union (3). Moreover, primitive forms of osteoporosis
(95% of cases) affect postmenopausal women (4) and both
males and females after 70 years of age (5). 
Fragility fractures are the most threatening complication of
osteoporosis. They are typically non-traumatic fractures or
they can be associated with low-energy ineffective trauma
(6); they usually occur at specific skeletal sites, such as dor-
sal and lumbar vertebral bodies, proximal hip, distal radius,
and proximal humerus (3). The incidence of osteoporotic
fractures amounts to nearly 9 millions/year worldwide, and
1.4 millions of these fractures are clinically symptomatic ver-
tebral fractures (2). 
Patients with fragility vertebral fractures can develop compli-
cations which can seriously compromise their health and
quality of life.   
Indeed, the presence of vertebral fractures leads to a 5-fold
increase in the risk of new vertebral fractures (Domino Ef-
fect) (7) and to a 2-3-fold increase in the risk of fragility frac-
tures at skeletal sites other than vertebral bodies (1). 
Moreover, back pain is typically associated with fragility ver-
tebral fractures. At the moment of the fracture occurrence,
back pain has an acute onset and is localized at the verte-
bral fracture site (8), so that the sudden occurrence of back
pain in absence of documentable injury often reveals a
fragility vertebral fracture in most osteoporotic patients. Back
pain can last for 4-6 weeks (8), but it tends to become chron-
ic in most patients: more than ¾ of whom complain of severe
back pain one year after the fracture (9).
Contrary to pathogenetic mechanisms of fragility vertebral
fracture-associated acute back pain, those of chronic back
pain are significantly less understood. It has been hypothe-
sized that bone marrow edema of the fractured vertebral
body might play a role (8). Moreover, fragility vertebral frac-
ture-associated height loss, dorsal kyphosis, and consequent
permanent contraction of paraspinal muscles, required to
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maintain the posture, can lead to spinal biomechanical
changes, thus promoting back pain chronicity (3, 8). Final-
ly, individual aspects of subjective pain perception have
been supposed to have a role (3). 
Current evidence shows that higher level of severity of ver-
tebral deformity is associated with higher risk of moderate
to severe back pain (10), and that more serious back pain-
related disability and worse quality of life are correlated
with more severe vertebral fracture (8). Dorsal vertebral
fractures and crush vertebral deformities are known to be
associated with worse prognosis in terms of complete resti-
tutio ad integrum and restoration of good health (11).
Chronic back pain is more frequent in the elderly population
and the increase of its frequency with increasing age (3)
can have two main reasons. 
The first one is that vertebral fracture risk is higher for el-
derly people than for young subjects, as age is a non-
changeable fracture risk factor itself (2). The prevalence of
osteoporosis increases with advancing age (3), as well as
the risk of fall because of senescence-associated sedative
drugs intake, visual defects, sarcopenia, and muscle weak-
ness (1).
The second reason is specifically related to the sarcopenia
and the muscle weakness which typically affect the elderly
population. They could induce gradual bone loss which in
turn could facilitate the development of dorsal kyphosis
even in absence of vertebral fractures; this deformity and
the consequent permanent muscle contraction could lead
to chronic back pain (3).
A future increase in the prevalence of osteoporosis is ex-
pected because of the progressive ageing of the general
population (5); consequently, a future increase of fragility
fractures and their associated complications and costs is
also expected (2), hence the problem of chronic back pain
in the elderly population is going to increase. This is a
problem of fundamental importance, because the presence
of persistent chronic pain in every single person, but espe-
cially in older subjects, can seriously jeopardize their health
and quality of life. Mood alterations, such as anxiety and
depression, sleep and hunger defects can develop as a
consequence of chronic pain. Gradual motor disability can
also derive from chronic persistence of back pain and can
increase the risk of immobilization which in turn can worsen
osteoporosis, thus increasing the risk of vertebral fracture
and, consequently, the risk of chronic back pain worsening.
Therefore, pain treatment is mandatory in everyone, partic-
ularly in elderly people, and the right of every patient to be
cured in order to mitigate and resolve pain is ratified by
law. 
Although the pain treatment has a very important value, it
also represents a quite complex challenge for clinicians
within their daily clinical practice. Elderly patients are often
affected by multiple comorbidities, hence they are treated
with multiple drugs. Therefore, the addition of an analgesic
as a new drug among those already taken can facilitate the
occurrence of one or more adverse effects which can wors-
en pre-existing diseases or even lead to the development
of new pathologies. Overall, this can seriously compromise
both already precarious health condition and already unsta-
ble psychophysical balance of elderly patients. 
Besides surgical treatment (vertebroplasty, kyphoplasty),
which are limited to selected cases, both opioids and non-
steroidal anti-inflammatory drugs (NSAIDs) are pharmaco-
logical therapies widely used for the treatment of back pain
associated with fragility vertebral fractures (3). 
NSAIDs are drugs of proven efficacy for the treatment of
this kind of pain, both as acute and chronic back pain (3,
12). Nevertheless, NSAIDs are burdened by a series of po-
tential adverse effects, such as gastrointestinal bleeding
and renal impairment (13). Therefore, the use of low-dose
analgesic drug could be a possible solution for the chal-
lenge of pain treatment in the elderly, that is the use of the
lowest effective dose of the drug which is able to control
symptoms, in order to limit potential side effects. This solu-
tion, which appears simple, can actually result quite com-
plex to be realized in clinical practice.
Among NSAIDs, diclofenac seems to represent a valid ther-
apeutic tool for this purpose. Indeed, diclofenac has a very
wide literature which can confirm both its efficacy as anti-
inflammatory, analgesic, and also antipyretic drug (12, 14,
15) and its tolerability. Many studies showed a lower risk of
complications and fewer side effects, particularly gastroin-
testinal ones, with the use of diclofenac rather than with the
use of the other NSAIDs (14, 16).
Diclofenac is a derivative of aminophenilacetic acid; it acts
through the inhibition of cyclooxygenase (COX) enzyme,
and it has a significantly higher affinity for the constitutive
form of the enzyme (COX-1) rather than for the induced
form (COX-2) (17). 
Diclofenac is available at low and very low-dose; its injec-
tive formulation can ensure a faster plasmatic absorption
and its subcutaneous formulation has the further advantage
of self-injection by the patient himself (18).
Study population
ImPAVeDic study will be performed in a group of 50 elderly
(≥ 65 years), male and female osteoporotic patients refer-
ring to the Mineral and Bone Metabolism Diseases Unit
who present with clinically-symptomatic (back pain) fragility
vertebral fractures. Patients will be enrolled independently
of the period of vertebral fracture occurrence, so that both
incident and prevalent vertebral fractures will be consid-
ered. Previous or current anti-fracture pharmacological
therapy will not be an exclusion criterion for patients’ re-
cruitment, whereas oncologic patients will be excluded. 
Patients who will meet these inclusion criteria and will also
receive the prescription of low-dose subcutaneous di-
clofenac as analgesic drug, in accordance with the routine
clinical practice, will be considered for the enrolment in the
present study. Selected patients will be enrolled after writ-
ten informed consent. 
Study procedures
Presence and intensity of back pain should always be eval-
uated in osteoporotic patients with fragility vertebral frac-
tures during medical examination and this will also be per-
formed with enrolled patients. 
Back pain will be evaluated using two specific pain evalua-
tion scales, the Visual Analogic Scale (VAS) and the Nu-
merical Rating Scale (NRS). 
Enrolled patients will receive the prescription of diclofenac
at a weight-dependent dose, particularly 25 milligrams
(mg)/millilitre (ml) 1 subcutaneous (sc) vial/day in case of
body weight < 50 ki lograms (Kg) and 50 mg/ml 1 sc
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vial/day if body weight ≥ 50 Kg. Diclofenac will be taken for
6 days long.
On the 7th day, patients will receive a phone call, during
which they will be asked to fill out again the pain evaluation
scales VAS and NRS, in order to detect changes in back
pain. In case of persistence of pain, analgesic therapy with
diclofenac may be temporarily continued according to the
medical opinion. 
Enrolled patients will undergo routine medical visits for pain
monitoring every month, for a period of time ranging from a
minimum of 2 months and a maximum of 6 months, which
will be individualized on the basis of the presence and the
extent of back pain complained by each single patient. At
each visit, VAS and NRS will be used again for pain moni-
toring. In case of back pain persistence, diclofenac will be
prescribed again, and it will be taken with the same modali-
ties of the first prescription. On the 7th day since the begin-
ning of every new 6-day regimen, back pain will be re-eval-
uated through a phone call asking patients to fill out again
VAS and NRS. 
Quality of life will be also evaluated using the specific
questionnaire SF-36. 
Objective, endpoint, and aim of the study
The objective of ImPAVeDic study is to evaluate the im-
provement of both back pain and quality of life in our study
population of patients treated with low-dose diclofenac and
longitudinally followed-up for a minimum period of time of 2
months and a maximum of 6 months, through the endpoint of
the evaluation of changes in VAS, NRS, and SF-36 question-
naire scores, respectively.
The aim of the present study is to demonstrate the improve-
ment of back pain in elderly patients affected by fragility ver-
tebral fractures with low-dose diclofenac. 
Conclusions
In conclusion, the possibility of giving patients the lowest
dose of a drug which is able to control symptoms can allow
to minimize the risk of the occurrence of adverse events,
thus leading to the optimization of patients’ care, especially
when the patient is elderly.
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